Reuters HealthThe U.S. Food and Drug administration granted priority review to Roche’s Actemra/RoActemra for the treatment of COVID-19 in hospitalized adults.
Coronavirus infections in Asia passed 100 million on March 30, according to a Reuters tally, as the region records a resurgence in cases dominated by the BA.2 Omicron sub-variant.
A sub-variant of the highly transmissible Omicron version of coronavirus known as BA.2 is now dominant worldwide, prompting surges in many countries in Europe and Asia and raising concern over the potential for a new wave in the United States.
Shanghai’s bespoke approach to tackling coronavirus outbreaks is coming under strain as new cases rise in the Chinese metropolis, with authorities reluctant to impose a comprehensive lockdown as other cities have done.
Adamis Pharmaceuticals Corporation announced that in studies conducted at Galveston National Laboratory (GNL), University of Texas Medical Branch (UTMB) at Galveston, hamsters challenged with high levels of the Omicron variant of the SARS-CoV-2 virus resulted in significant decrease of inflammation in the lungs of animals treated with Tempol compared to controls.
The most obvious risks from COVID-19 are hospitalization and death. But study after study shows the disease comes with an increased risk of a number of health problems, including diabetes.
The immune response to COVID-19 helps protect against reinfection, but that protection is weaker against Omicron than it was against earlier variants of the coronavirus, according to new data. In other news, protection provided by booster shots of the mRNA vaccines from Moderna Inc. or Pfizer Inc. and partner BioNTech SE starts waning quickly, according to data published in Feb. 11th’s Morbidity and Mortality Weekly Report from the U.S. Centers for Disease Control and Prevention (CDC).
Virologist Luc Montagnier passed away, French news agency AFP reported on February 10. Montagnier won a Nobel Prize for his part in discovering the human immunodeficiency virus (HIV) that causes AIDS,
The Omicron variant was estimated to be 95.4% of the coronavirus strains circulating in the United States as of Jan. 1, the U.S. Centers for Disease Control and Prevention (CDC) said on January 4.
The Omicron variant of the coronavirus is spreading faster than the Delta variant and is causing infections in people already vaccinated or who have recovered from the Covid-19 disease, the head of the World Health Organization (WHO) said on December 20.
